Vascular Biology |
From the National Creative Research Initiatives Center for Cardiac Regeneration and Institute of Cardiovascular Research (J.K.C., I.K., H.G.K, J.K.K., G.Y.K.) and the Departments of Nuclear Medicine (S.T.L), Pathology (M.J.C), and Internal Medicine (W.H.K), Chonbuk University Medical School, Chonju, Korea.
Correspondence to Gou Young Koh, MD, PhD, National Creative Research Initiatives Center for Cardiac Regeneration, Chonbuk National University Medical School, San 2-20, Keum-Am-Dong, Chonju, 560-180, Republic of Korea. E-mail gykoh{at}moak.chonbuk.ac.kr
AbstractUsing growth factors to induce vasculogenesis is a promising approach in the treatment of ischemic legs and myocardium. Because the vasculogenesis requires a cascade of growth factors, their receptors, and intracellular signals, such therapies may require the application of more than a single growth factor. We examined the effect of 2 endothelial cellspecific growth factors, angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF), on primary cultured porcine coronary artery endothelial cells. VEGF, but not Ang1, increased DNA synthesis and cell number. Ang1 or VEGF induced migration and sprouting activity, increased plasmin and matrix metalloproteinase-2 secretion, and decreased tissue inhibitors of metalloproteinase type 2 secretion. A combination of the submaximal doses of Ang1 and VEGF enhanced these effects and was more potent than the maximal dose of either alone. In a rabbit ischemic hindlimb model, a combination of Ang1 and VEGF gene delivery produced an enhanced effect on resting and maximal blood flow and capillary formation that was greater than that of either factor alone. Angiographic analyses revealed that larger blood vessels were formed after gene delivery of Ang1 or Ang1 plus VEGF than after VEGF gene delivery. These results suggest that combined treatment of Ang1 and VEGF could be used to produce therapeutic vascularization.
Key Words: angiopoietin-1\b vascular endothelial growth factor\b vascularization
This article has been cited by other articles:
![]() |
W. S.N. Shim, I. A.W. Ho, and P. E.H. Wong Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis Mol. Cancer Res., July 1, 2007; 5(7): 655 - 665. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Carr, B. W. Howard, H. T. Yang, E. Eby-Wilkens, P. Loos, A. Varbanov, A. Qu, J. P. DeMuth, M. G. Davis, A. Proia, et al. Efficacy of systemic administration of SDF-1 in a model of vascular insufficiency: Support for an endothelium-dependent mechanism Cardiovasc Res, March 1, 2006; 69(4): 925 - 935. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Cascone, L. Napione, F. Maniero, G. Serini, and F. Bussolino Stable interaction between {alpha}5{beta}1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1 J. Cell Biol., September 12, 2005; 170(6): 993 - 1004. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chalothorn, H. Zhang, J. A. Clayton, S. A. Thomas, and J. E. Faber Catecholamines augment collateral vessel growth and angiogenesis in hindlimb ischemia Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H947 - H959. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Cho, K. E. Kim, J. Byun, H.-S. Jang, D.-K. Kim, P. Baluk, F. Baffert, G. M. Lee, N. Mochizuki, J. Kim, et al. Long-Term and Sustained COMP-Ang1 Induces Long-Lasting Vascular Enlargement and Enhanced Blood Flow Circ. Res., July 8, 2005; 97(1): 86 - 94. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-T. Kim, H.-H. Choi, M. O. Steinmetz, B. Maco, R. A. Kammerer, S. Y. Ahn, H.-Z. Kim, G. M. Lee, and G. Y. Koh Oligomerization and Multimerization Are Critical for Angiopoietin-1 to Bind and Phosphorylate Tie2 J. Biol. Chem., May 20, 2005; 280(20): 20126 - 20131. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Madeddu Therapeutic angiogenesis and vasculogenesis for tissue regeneration Exp Physiol, May 1, 2005; 90(3): 315 - 326. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Markkanen, T. T. Rissanen, A. Kivela, and S. Yla-Herttuala Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart-gene therapy Cardiovasc Res, February 15, 2005; 65(3): 656 - 664. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. Lloyd, B. M. Prior, H. Li, H. T. Yang, and R. L. Terjung VEGF receptor antagonism blocks arteriogenesis, but only partially inhibits angiogenesis, in skeletal muscle of exercise-trained rats Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H759 - H768. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kinnaird, E. Stabile, M. S. Burnett, and S. E. Epstein Bone Marrow-Derived Cells for Enhancing Collateral Development: Mechanisms, Animal Data, and Initial Clinical Experiences Circ. Res., August 20, 2004; 95(4): 354 - 363. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. F. Zhou, E. Stabile, J. Walker, M. Shou, R. Baffour, Z. Yu, D. Rott, G. D. Yancopoulos, J. S. Rudge, and S. E. Epstein Effects of gene delivery on collateral development in chronic hypoperfusion: Diverse effects of angiopoietin-1 versus vascular endothelial growth factor J. Am. Coll. Cardiol., August 18, 2004; 44(4): 897 - 903. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. LEE, C.-H. CHO, S.-J. HWANG, H.-H. CHOI, K.-T. KIM, S. Y. AHN, J.-H. KIM, J.-L. OH, G. M. LEE, and G. Y. KOH Biological characterization of angiopoietin-3 and angiopoietin-4 FASEB J, August 1, 2004; 18(11): 1200 - 1208. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Carr, M. G. Davis, E. Eby-Wilkens, B. W. Howard, B. A. Towne, T. E. Dufresne, and K. G. Peters Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H268 - H276. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Cho, R. A. Kammerer, H. J. Lee, M. O. Steinmetz, Y. S. Ryu, S. H. Lee, K. Yasunaga, K.-T. Kim, I. Kim, H.-H. Choi, et al. COMP-Ang1: A designed angiopoietin-1 variant with nonleaky angiogenic activity PNAS, April 13, 2004; 101(15): 5547 - 5552. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Cho, R. A. Kammerer, H. J. Lee, K. Yasunaga, K.-T. Kim, H.-H. Choi, W. Kim, S. H. Kim, S. K. Park, G. M. Lee, et al. Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis PNAS, April 13, 2004; 101(15): 5553 - 5558. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kinnaird, E. Stabile, M.S. Burnett, C.W. Lee, S. Barr, S. Fuchs, and S.E. Epstein Marrow-Derived Stromal Cells Express Genes Encoding a Broad Spectrum of Arteriogenic Cytokines and Promote In Vitro and In Vivo Arteriogenesis Through Paracrine Mechanisms Circ. Res., March 19, 2004; 94(5): 678 - 685. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hijjawi, J. E. Mogford, L. A. Chandler, K. J. Cross, H. Said, B. A. Sosnowski, and T. A. Mustoe Platelet-Derived Growth Factor B, but Not Fibroblast Growth Factor 2, Plasmid DNA Improves Survival of Ischemic Myocutaneous Flaps Arch Surg, February 1, 2004; 139(2): 142 - 147. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. G. Peters, C. D. Kontos, P. C. Lin, A. L. Wong, P. Rao, L. Huang, M. W. Dewhirst, and S. Sankar Functional Significance of Tie2 Signaling in the Adult Vasculature Recent Prog. Horm. Res., January 1, 2004; 59(1): 51 - 71. [Abstract] [Full Text] |
||||
![]() |
K. Kondoh, H. Koyama, T. Miyata, T. Takato, H. Hamada, and H. Shigematsu Conduction performance of collateral vessels induced by vascular endothelial growth factor or basic fibroblast growth factor Cardiovasc Res, January 1, 2004; 61(1): 132 - 142. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Chhokar and A. L. Tucker Angiogenesis: Basic Mechanisms and Clinical Applications Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 253 - 280. [Abstract] [PDF] |
||||
![]() |
O. Stoeltzing, S. A. Ahmad, W. Liu, M. F. McCarty, J. S. Wey, A. A. Parikh, F. Fan, N. Reinmuth, M. Kawaguchi, C. D. Bucana, et al. Angiopoietin-1 Inhibits Vascular Permeability, Angiogenesis, and Growth of Hepatic Colon Cancer Tumors Cancer Res., June 15, 2003; 63(12): 3370 - 3377. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Babaei, K. Teichert-Kuliszewska, Q. Zhang, N. Jones, D. J. Dumont, and D. J. Stewart Angiogenic Actions of Angiopoietin-1 Require Endothelium-Derived Nitric Oxide Am. J. Pathol., June 1, 2003; 162(6): 1927 - 1936. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. White, S. Shan, C. P. Rusconi, G. Shetty, M. W. Dewhirst, C. D. Kontos, and B. A. Sullenger Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2 PNAS, April 29, 2003; 100(9): 5028 - 5033. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Satchell, S. J. Harper, J. E. Tooke, D. Kerjaschki, M. A. Saleem, and P. W. Mathieson Human Podocytes Express Angiopoietin 1, a Potential Regulator of Glomerular Vascular Endothelial Growth Factor J. Am. Soc. Nephrol., February 1, 2002; 13(2): 544 - 550. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kim, S.-O. Moon, S. K. Park, S. W. Chae, and G. Y. Koh Angiopoietin-1 Reduces VEGF-Stimulated Leukocyte Adhesion to Endothelial Cells by Reducing ICAM-1, VCAM-1, and E-Selectin Expression Circ. Res., September 14, 2001; 89(6): 477 - 479. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |